News

The combined company is expected to have multiple proprietary RNAi drug discovery platforms with the capability to deliver RNAi-based therapeutics via systemic, local and oral administration. In addition,

The merger, structured as a tax-free, all-stock merger of equals, was approved by both companies’ boards of directors. On a combined basis, Accelrys and Sym have a pre-announcement

Red blood cell fatty acid composition reflects long-term intake of EPA and DHA, and are also highly correlated with the amount of fatty acids found in heart tissue.

In the published study, Gilles Blancho and colleagues from the Institute of Transplantation – Urology – Nephrology (ITUN) in Nantes, France, have demonstrated that Pharming’s rhC1INH prevented AMR

The Phase II study, known as SG005, uses the company’s exclusively in-licensed formulation of inhaled IFN-beta (SNG001) and aims to assess the efficacy and safety of inhaled SNG001

Ardea Biosciences said that in the 28-day, randomised, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia, received 200mg once-daily (qd) RDEA594, 400mg qd RDEA594, 600mg qd RDEA594

Takeda Pharmaceutical has received an exclusive license to Feraheme for all therapeutic applications in 5 regions, including Europe, Canada, Turkey, the Commonwealth of Independent States and Asia Pacific

Moexipril HCl is the generic equivalent of Univasc tablets, marketed by Schwarz. The product is indicated for the treatment of patients with hypertension. Reportedly, in March 2010, Glenmark

Orexigen Therapeutics said that the NDA for Contrave is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over